Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has provided an update.
Shanghai Henlius Biotech, Inc. has announced its upcoming Annual General Meeting (AGM) scheduled for May 8, 2025, where shareholders will consider and approve various resolutions. These include the company’s annual report, financial accounts, profit distribution, and budget proposals for the years 2024 and 2025. Additionally, the meeting will address the re-appointment of auditors and remuneration packages. A special resolution will be considered to grant the board a mandate to issue shares, which could impact the company’s capital structure and market operations.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a biotechnology company based in China, focusing on the development and commercialization of monoclonal antibody drugs. The company operates within the pharmaceutical industry, with a market focus on providing innovative therapeutic solutions.
YTD Price Performance: 20.68%
Average Trading Volume: 1,613,942
Technical Sentiment Signal: Sell
Current Market Cap: HK$15.54B
For detailed information about 2696 stock, go to TipRanks’ Stock Analysis page.